Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial.

Emamikia S, Gentline C, Chatzidionysiou K, Arnaud L, van Vollenhoven R.

Scand J Rheumatol. 2018 Mar;47(2):131-140. doi: 10.1080/03009742.2017.1336570. Epub 2017 Sep 1.

PMID:
28862513
2.

Medicine Based Evidence for Individualized Decision Making: Case Study of Systemic Lupus Erythematosus.

Wivel AE, Lapane K, Kleoudis C, Singer BH, Horwitz RI.

Am J Med. 2017 Nov;130(11):1290-1297.e6. doi: 10.1016/j.amjmed.2017.06.013. Epub 2017 Jul 12.

PMID:
28711556
3.

A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.

Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, Gordon D.

Lupus. 2017 Dec;26(14):1483-1490. doi: 10.1177/0961203317703495. Epub 2017 May 3.

4.

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.

Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7.

5.

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.

Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B.

Lupus. 2016 Dec;25(14):1587-1596. Epub 2016 Aug 3.

6.

Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.

Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, Gatto M, Piantoni S, Nalotto L, Franceschini F, Larosa M, Fredi M, Punzi L, Tincani A, Doria A.

Arthritis Care Res (Hoboken). 2017 Jan;69(1):115-123. doi: 10.1002/acr.22971. Epub 2016 Nov 18.

7.

Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.

Struemper H, Murtaugh T, Gilbert J, Barton ME, Fire J, Groark J, Fox NL, Roth D, Gordon D.

Clin Pharmacol Drug Dev. 2016 May;5(3):208-15. doi: 10.1002/cpdd.219. Epub 2015 Dec 4.

8.

Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.

Yapa SW, Roth D, Gordon D, Struemper H.

Lupus. 2016 Nov;25(13):1448-1455. doi: 10.1177/0961203316642309. Epub 2016 Jul 11.

9.

Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.

van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, Tang Y, Thompson A.

Arthritis Rheumatol. 2016 Sep;68(9):2184-92. doi: 10.1002/art.39682.

10.

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.

Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, Wilson B, Molta C, Roth D, Gordon D.

Lupus. 2016 Jun;25(7):699-709. doi: 10.1177/0961203315625119. Epub 2016 Mar 1.

11.

Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.

Quartuccio L, Salvin S, Corazza L, Gandolfo S, Fabris M, De Vita S.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):311-4. Epub 2016 Feb 9.

PMID:
26886154
12.

Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study.

Seror R, Nocturne G, Lazure T, Hendel-Chavez H, Desmoulins F, Belkhir R, Ravaud P, Benbijja M, Poirier-Colame V, Taoufik Y, Mariette X.

Arthritis Res Ther. 2015 Sep 4;17:241. doi: 10.1186/s13075-015-0750-y.

13.

Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.

De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, Nocturne G, Gandolfo S, Isola M, Mariette X.

Rheumatology (Oxford). 2015 Dec;54(12):2249-56. doi: 10.1093/rheumatology/kev257. Epub 2015 Aug 4.

PMID:
26242856
14.

Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.

Pontarini E, Fabris M, Quartuccio L, Cappeletti M, Calcaterra F, Roberto A, Curcio F, Mavilio D, Della Bella S, De Vita S.

Rheumatology (Oxford). 2015 Aug;54(8):1429-34. doi: 10.1093/rheumatology/kev005. Epub 2015 Mar 3.

PMID:
25740829
15.

Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients.

Andreoli L, Reggia R, Pea L, Frassi M, Zanola A, Cartella S, Franceschini F, Tincani A.

Isr Med Assoc J. 2014 Oct;16(10):651-3. No abstract available.

16.

Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.

Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, Desmoulins F, Nocturne G, Ravaud P, De Vita S.

Ann Rheum Dis. 2015 Mar;74(3):526-31. doi: 10.1136/annrheumdis-2013-203991. Epub 2013 Dec 17.

PMID:
24347569
17.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

18.

The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers.

Shida Y, Takahashi N, Sakamoto T, Ino H, Endo A, Hirama T.

J Clin Pharm Ther. 2014 Feb;39(1):97-101. doi: 10.1111/jcpt.12101. Epub 2013 Oct 5.

PMID:
24117862
19.

A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.

Bishton M, Spencer A, Dickinson M, Ritchie D.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):575-8. doi: 10.1016/j.clml.2013.04.006. Epub 2013 Jun 15.

PMID:
23773449
20.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

Supplemental Content

Loading ...
Support Center